References: |
Product Reference:
?VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity: J.D. Loike; Cancer Chemother. Pharmacol. 7, 103 (1982)
?Antitumor agents. I. DNA topoisomerase II inhibitory activity and the structural relationship of podophyllotoxin derivatives as antitumor agents: T. Terada, et al.; Chem. Pharmacol. Bull. (Tokyo) 40, 2720 (1992)
?Antineoplastic and antiviral activities of podophyllotoxin related lignans: M. Gordaliza, et al.; Arch. Pharmacol. 327, 175 (1994)
?Podophyllotoxin: C. Canel, et al.; Phytochemistry 54, 115 (2000) (Review)
?Antitumor properties of podophyllotoxin and related compounds: M. Gordaliza, et al.; Curr. Pharm. Des. 6, 1811 (2000) (Review)
?Drugs that inhibit tubulin polymerization: the particular case of podophyllotoxin and analogues: S. Desbene & S. Giorgi-Renault; Curr. Med. Chem. Anticancer Agents 2, 71 (2002) (Review)
?Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents: Y. You; Curr. Pharm. Des. 11, 1695 (2005) (Review)
?Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile: J.T. Hartmann & H.P. Lipp; Drug Saf. 29, 209 (2006) (Review)
?An evidence-based review of medical and surgical treatments of genital warts: N. Scheinfeld & D.S. Lehman; Dermatol. Online J. 12, 5 (2006)
? |